Addressing gaps in care and insights
Gastroenterology disorders affect up to 11% of the U.S. population. Irritable Bowel Diseases (IBD), such as crohn’s disease and ulcerative colitis, are lifelong conditions that cause chronic inflammation in the intestines, leading to pain and swelling in patients. Other conditions like NASH, are difficult to diagnose and have few treatment options.
Gastroenterology conditions are complex. Accessing data shouldn’t be.
Understanding the complexities of these systemic inflammatory diseases, and the factors that affect response to treatments, drives our focus on bringing a dynamic new approach to real world evidence generation to healthcare stakeholders.
Meet the data network focused on Gastroenterology disorders
A comprehensive view of the patient journey from clinical development to the clinic
Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to empower your programs shouldn’t be. That’s why OM1 built the largest gastroenterology network in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.
• Crohn’s Disease
Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.
CD patients with deep clinical data including specialist’s notes and many with extracted and calculated CDAI
Extracted and Calculated CDAI scores
UC patients with deep clinical data and many with extracted and calculated Mayo scores
Extracted and Calculated Mayo scores
NASH patients with deep clinical data including many with liver biopsy results
*Data counts as of Q3 2022 ©OM1 Gastroenterology Data Specialty Area
From evidence to insights
Assessing the impact of changes in the management of Ulcerative Colitis patients who have an incomplete response to TNFa Therapy
Lack of treatment options resulted in UC patients left on TNFa with dose intensification, adjunct steroids or other therapy combinations despite failing to achieve remission. How has the approval of novel therapies changed practice and patient outcomes?
Leveraging Observed and Calculated CDAI Scores in Patients with Crohn’s Disease to Understand Response to Therapy
The Crohn’s Disease Activity Index (CDAI) is used in clinical practice and randomized control trials (RCTs) to assess the patient’s clinical status, to select appropriate therapies, and to assess the response to treatments. Despite the value of the CDAI score, it is not frequently assessed in clinical setting.
Identification of both probable and confirmed non-alcoholic fatty liver disease (NAFLD) and NASH is hampered by asymptomatic disease, under-diagnosis in routine care, lack of condition-specific treatments and poor billing code specificity.
How we can help
Our specialized real world data, deep research teams, and physician experts offer you the longitudinal patient journeys and critical outcomes to enable your teams with the rapid and in-depth analyses necessary to drive your critical business objectives.
Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as seeing where unmet needs are greatest or determining which groups the protocol should be designed to enroll.
Measure key safety outcomes of interest and support regulatory requirements, such as monitoring and comparing the real-world safety profiles for patients on biologics.
Align with real world-based patient behaviors to measure adherence to novel treatment approaches for IBD-related conditions.
Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization. For example, to assess the cost effectiveness of early treatment interventions for CD and/or UC.
RWD can help guide planning, forecasting, and improving brand performance, such as understanding the size of the market by segment in patient subtypes that are best aligned with a brand’s positioning.
Meet our Clinician Lead
Gary Curhan, MD, ScD is the Chief Medical Officer of OM1, Inc. He is a practicing nephrologist in Boston. Dr. Curhan has published widely on the epidemiology of many medical conditions including cardiovascular disease, hypertension, kidney stones, gout, hearing loss and others. His research in several large cohort studies, including the Nurses’ Health Studies and the Health Professionals Follow-Up Study, focuses on the prevention of common diseases by investigating scientifically and clinically important questions and exploring the role of modifiable factors and has been supported continuously for over 25 years by the National Institutes of Health. He was the Editor-in-Chief of the Clinical Journal of the American Society of Nephrology, a leading nephrology journal. He has served on many national and international advisory committees, including the National Institutes of Health. He has mentored numerous individuals, many of whom now hold leadership positions at major academic institutions and public companies.
Dr. Curhan is a graduate of Brown University, Harvard Medical School and Harvard School of Public Health. Prior to joining OM1, he was a Professor of Medicine at Harvard Medical School and Professor of Epidemiology at Harvard School of Public Health.